What is the typical dosing of Polymyxin B (polymyxin B) in units for treating infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Polymyxin B Dosing in Units

Polymyxin B is dosed at 15,000 to 25,000 units/kg/day for adults and children with normal renal function, with 1 mg of polymyxin B equal to 10,000 units. 1

Standard Dosing Regimens

Intravenous Administration

  • Adults and children: 15,000 to 25,000 units/kg body weight/day, divided every 12 hours, with a maximum daily dose not exceeding 25,000 units/kg/day 1
  • Infants with normal kidney function: May receive up to 40,000 units/kg/day 1
  • Premature and newborn infants: Doses as high as 45,000 units/kg/day have been used in limited studies for Pseudomonas aeruginosa sepsis 1

Intramuscular Administration (Not Routinely Recommended)

  • Adults and children: 25,000 to 30,000 units/kg/day, divided at 4 or 6 hour intervals 1
  • Note: IM route causes severe pain at injection sites, particularly in infants and children 1

Intrathecal Administration

  • Adults and children over 2 years: 50,000 units once daily for 3-4 days, then 50,000 units every other day for at least 2 weeks after CSF cultures are negative 1
  • Children under 2 years: 20,000 units once daily for 3-4 days, then 25,000 units every other day 1

Critical Dosing Conversion

The unit conversion for polymyxin B is: 1 mg = 10,000 units 2, 1

This differs significantly from colistin, where 1 million IU = approximately 80 mg of colistimethate sodium (CMS) = 33 mg colistin base activity 2, 3, 4

Dosing in Renal Impairment

Polymyxin B does NOT require dose adjustment based on renal function, unlike colistin. 5, 6

  • Population pharmacokinetic studies demonstrate that polymyxin B clearance shows no correlation with creatinine clearance (r² = 0.008) 6
  • Polymyxin B is predominantly non-renally cleared, with median urinary recovery of only 4.04% 6
  • Total body clearance scaled by weight (0.0276 L/hour/kg) shows remarkably low interindividual variability (32.4% coefficient of variation) regardless of renal function 6
  • However, recent evidence suggests dose adjustment may improve outcomes in renal insufficiency, with a loading dose of 2-2.5 mg/kg and maintenance of 1.5-3 mg/kg/day recommended 7, 8

Dosing for Specific Infections

Carbapenem-Resistant Gram-Negative Infections

  • Bloodstream infections and pneumonia: Polymyxin B 2.5-3.0 mg/kg/day divided in 2 daily IV doses (equivalent to 25,000-30,000 units/kg/day) 2
  • Combination therapy is strongly preferred over monotherapy for carbapenem-resistant infections 2

Hospital-Acquired/Ventilator-Associated Pneumonia

  • Loading dose: 2.5-3.0 mg/kg IV 2
  • Maintenance: 2.5-3.0 mg/kg/day divided in 2 doses 2

Critical Implementation Considerations

Loading Dose Strategy

  • Unlike colistin, the FDA label does not specify a loading dose for polymyxin B 1
  • However, clinical practice guidelines suggest a loading dose of 2-2.5 mg/kg to rapidly achieve therapeutic levels 7

Inadequate Dosing Pitfall

Doses below 15,000 units/kg/day (<1.5 mg/kg/day) are independently associated with treatment failure and increased mortality in critically ill patients 9

  • Low polymyxin B doses were the strongest predictor of treatment failure (p = 0.002) and in-hospital mortality (p = 0.007) 9
  • Mortality rate in one ICU cohort was 48.8%, with 82.9% attributed to treatment failure 9

Renal Replacement Therapy

  • Continuous renal replacement therapy (CRRT): No dose adjustment necessary for polymyxin B 7, 3
  • Intermittent hemodialysis: Standard dosing can be maintained 7
  • This represents a significant advantage over colistin, which requires complex dose adjustments 3, 4

Nephrotoxicity Monitoring

  • Monitor renal function closely during therapy, though polymyxin B is associated with lower incidence and later onset of nephrotoxicity compared to colistin 7, 4
  • Avoid concurrent nephrotoxic agents, particularly the combination of NSAIDs, diuretics, and ACE inhibitors/ARBs 7
  • Consider therapeutic drug monitoring where available 2

Preparation and Storage

  • Dissolve 500,000 polymyxin B units in 300-500 mL of 5% Dextrose Injection for IV continuous drip 1
  • Solutions should be stored under refrigeration and unused portions discarded after 72 hours 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Colistin Dosage Administration in Patients with Impaired Renal Function

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Colistin and Polymyxin B Differences

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013

Guideline

Management of Polymyxin-Associated Acute Kidney Injury (AKI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.